Kizoo Technology Capital invests in early-stage rejuvenation/longevity biotech companies. Their investment thesis centers around addressing the root causes of aging to prevent and reverse age-related diseases. They specifically target technologies that aim to reverse or repair age-related cellular changes, such as molecular waste, calcification, tissue stiffening, loss of stem cell function, genetic alterations, and impaired energy production. Kizoo focuses on funding technologies that have the potential to significantly extend healthy lifespans. The firm seeks out "never-done-before" technologies with exceptional global impact potential. They position themselves as investors in companies that are pushing the boundaries of what's possible in the field of longevity. Kizoo's approach involves backing companies developing novel therapeutics and approaches to tackle fundamental aging mechanisms. Kizoo's activities are aligned with the mission of their sister organization, Forever Healthy, suggesting a synergistic approach to longevity investment and research. They actively support companies that spun out of or are co-funded by the Forever Healthy Foundation and SENS Research Foundation. This suggests a strategy that builds upon and complements existing research and initiatives in the aging field.
Preferred startup development maturity for initial funding deployment.
Rejuvenation biotech, Longevity biotech, Age-related disease therapeutics, Vascular disease, Arterial plaque removal, Tissue calcification reversal, Crosslink-breaking drugs, Stem cell rejuvenation
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...